Kyverna Therapeutics’ CAR-T cell therapy shows promise against autoimmune diseases

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags CAR T cell therapy CAR-T cell and gene therapy

Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases.

In a landmark study involving 50 patients, KYV-101, an autologous, fully human anti-CD19 CAR-T cell therapy, has demonstrated broad efficacy across a diverse range of autoimmune conditions.

KYV-101 has shown promising results in treating 12 different autoimmune conditions, including systemic lupus erythematosus (SLE) and myasthenia gravis (MG), suggesting its potential as a universal treatment.

Furthermore, patients have experienced sustained disease and drug-free remission for over a year, marking a significant milestone in managing chronic conditions.

The trials, conducted across 12 sites in Europe and the U.S., have also confirmed KYV-101's efficacy across diverse populations and healthcare systems.

The data, which surpasses that of any other company in terms of patient diversity and number treated, will be presented at the EULAR 2024 symposium in a session titled ‘Anti-CD19 CAR-T Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond.’

The symposium will feature insights from leading experts in rheumatology and neurology, including Dr. Gerhard Krönke, Dr. Peter Merkel, Dr. Richard Furie, Dr. Roberto Caricchio, Dr. James Chung, and Kyverna CEO Peter Maag.

“CAR-T cell therapies are rapidly establishing themselves as the new North star in the autoimmune disease treatment universe,” said Maag.

“We are seeing rising interests in unlocking the full potential of cell therapies in rheumatological and neurological B cell-driven autoimmune diseases.”

KYV-101 is designed to utilize the patient’s own modified immune cells to target B cell-driven autoimmune diseases. Initially developed by the National Institutes of Health (NIH), it first showed promise in a 20-patient phase 1 oncology trial.

Kyverna will also present two posters on June 12 detailing the preclinical development of KYV-201, their allogeneic product candidate, and proteomic markers associated with CAR-T therapeutic response in autoimmune diseases. The company will have an exhibit at booth E22-23 for healthcare practitioners and patient advocates.

With the promising data from KYV-101, Kyverna Therapeutics is poised to make significant strides in the fight against autoimmune diseases.

Related news

Follow us